Project Grant HT94252310988
Award Date 9/1/23
Completion Date 9/14/26
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Finland
Similar Awards
- The U.S. Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), has awarded a $954,000 project grant to the Massachusetts Institute of Technology (MIT) for the research project "TUMOR-TARGETED NANOCARRIERS FOR EFFECTIVE IMMUNOMODULATION OF OVARIAN CANCER". The grant, with a performance period from May 1, 2025 to April 30, 2028, will support advanced biomedical research aimed at developing innovative medical solutions for military personnel...
- The Defense Health Agency awarded Dana-Farber Cancer Institute a $1,046,135 project grant under the Military Medical Research and Development program to conduct research titled "Drugging the Undruggable: Programming Ovarian Cancer Cells as the Next-Generation Immunotherapy." The three-year award runs from May 15, 2023 to May 14, 2026. As the prime recipient, Dana-Farber will leverage its expertise in tumor biology, immunology and drug development to research new therapies for ovarian...
- This $405,000 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports Panorama Research Incorporated's development of a novel antibody-based immunotherapy to enhance ovarian tumor responses to treatment. The project aims to create a switchable split superantigen fused with antibodies targeting binary tumor-specific receptors, with the goal of boosting the effectiveness of immunotherapy for ovarian cancer patients. As a...
- The University of Ottawa has been awarded a $299,760 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "HARNESSING INNATE LYMPHOID CELLS TO BOOST THE EFFICACY OF IMMUNOTHERAPY IN OVARIAN CANCER". The grant, which has a performance period from August 15, 2025 to August 14, 2027, will support advanced biomedical research aimed at transforming healthcare for military service members, veterans,...
- This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development federal grant program (CFDA 12.420), provides $705,038 to Yale University for the "Development of GUAR-T as a Novel Class of Universal Cellular Immunotherapies for Ovarian Cancer." The project aims to conduct advanced biomedical research to transform healthcare for military service members, veterans, and the general public by developing innovative immunotherapies for ovarian...
- This federal Project Grant award of $778,092.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports preclinical studies of a dual-targeted fine-tuned immune-restoring (DFIR) CAR-T cell therapy approach for treating high-grade serous ovarian cancer. The award was made to the Dana-Farber Cancer Institute, Inc. (DFCI), a leading cancer research and treatment center in Boston, MA, on April 15, 2025, with a planned completion date of April 14,...
- The Project Grant award of $1,104,000.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides funding to the Scripps Research Institute in La Jolla, CA to conduct research on "TUMOR-TARGETED NANOCARRIERS FOR EFFECTIVE IMMUNOMODULATION OF OVARIAN CANCER." The award period runs from May 1, 2025 to April 30, 2028. This research aims to develop innovative, tumor-targeted nanocarrier technologies to enhance immunotherapeutic...
- This $2,014,500 project grant from the Defense Health Agency was awarded to Health Research, Inc. - Roswell Park Division to conduct a randomized Phase 2 clinical trial evaluating pembrolizumab combined with bevacizumab, with or without the anti-CD40 agonist CDX-1140, in patients with recurrent ovarian cancer. The grant was provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for...
- The Defense Health Agency awarded a $1,290,499.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "ENHANCING THE ANTITUMOR ACTIVITY OF NATURAL KILLER CELLS IN OVARIAN CANCER," is focused on conducting research to develop innovative approaches to understanding, detecting, and treating ovarian cancer. DFCI, a prestigious non-profit cancer research center, will...
- The Defense Health Agency awarded a $1,598,801 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a Phase 1B study of the BCL-XL degrader DT2216 combined with paclitaxel in recurrent platinum-resistant ovarian cancer. This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports advanced biomedical research to transform healthcare for military service members and the public. The study aims to investigate the efficacy of...